PharmaCord LLC, a prominent provider of patient services in the pharmaceutical sector, has appointed Robert Truckenmiller as its new Chief Executive Officer, effective January 31, 2025. Truckenmiller brings nearly 25 years of experience in the pharmaceutical industry, most recently serving as Senior Vice President and Head of U.S. Vaccines at GSK.

Nitin Sahney, the founder and outgoing CEO of PharmaCord, will remain on the Board of Directors and continue as a significant investor. Since its inception in 2017, Sahney has transformed PharmaCord into a key partner for major pharmaceutical companies, leveraging technology to enhance patient experiences. He expressed confidence in Truckenmiller's leadership, highlighting his extensive industry relationships and commitment to innovation.

Jon Maschmeyer, a Partner at Permira and a board member at PharmaCord, praised Sahney's visionary leadership and emphasized Truckenmiller's potential to drive the company's growth. Maschmeyer noted that Truckenmiller's focus on innovation and understanding of customer needs will be crucial for PharmaCord's future success.

Truckenmiller expressed enthusiasm for his new role, citing PharmaCord's dedication to improving patient experiences through better access to treatments and therapy adherence. He aims to build on the company's achievements alongside its talented management team and board.

Before joining GSK, Truckenmiller held various leadership positions in sales, marketing, and market access at companies like EMD Serono, UCB Inc., and Johnson & Johnson. He holds a Bachelor of Science in Marketing and an MBA in Finance from the University of Central Florida and is a U.S. Coast Guard veteran.

Permira, which acquired PharmaCord in September 2024, aims to support the company's growth and expansion of its tech-enabled services. This investment aligns with Permira's strategy of driving long-term value creation and sustainable growth in the healthcare sector.